SCHEMBL21241955

SCHEMBL21241955

CSCCC(NC(=O)c1ccc(O)cc1)C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.53
ADORA3 P0DMS8 1/20 0.52
PARP1 P09874 1/20 0.50
PHGDH O43175 3/20 0.49
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
MAPT P10636 2/20 0.49
MEN1 O00255 1/20 0.48
CRHBP P24387 1/20 0.48
KMT2A Q03164 1/20 0.48
CRHR2 Q13324 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22971536 1.00 SCD (0.53) SCDADORA3PARP1PHGDHALDH1A1
SCHEMBL21224324 0.94 SCD (0.57) SCDADORA3PARP1PHGDHALDH1A1
SCHEMBL21224323 0.94 SCD (0.57) SCDADORA3PARP1PHGDHALDH1A1
SCHEMBL21225186 0.93 SCD (0.54) SCDADORA3PARP1PHGDHALDH1A1
SCHEMBL21225185 0.93 SCD (0.54) SCDADORA3PARP1PHGDHALDH1A1
SCHEMBL21225227 0.92 SCD (0.53) SCDADORA3PARP1PHGDHALDH1A1
SCHEMBL21224219 0.92 SMN1; SMN2 (0.53) SCDADORA3PARP1PHGDHALDH1A1
SCHEMBL21224221 0.92 SMN1; SMN2 (0.53) SCDADORA3PARP1PHGDHALDH1A1
SCHEMBL21225226 0.92 SCD (0.53) SCDADORA3PARP1PHGDHALDH1A1
SCHEMBL21224711 0.91 SCD (0.52) SCDADORA3PARP1PHGDHALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
CN-112153984-A Compound and use thereof 福宏治疗公司 2020-12-29 CN disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SCD 3594/4885ADORA3 3993/4885PARP1 491/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB SCD 3594/4885ADORA3 3993/4885PARP1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.